SCHEMBL24176377

SCHEMBL24176377

COC(=O)c1ccc(C)c(Oc2cccc3ccccc23)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
ESRRA P11474 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
KIF11 P52732 1/20 0.45
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
MAPK1 P28482 2/20 0.44
PGR P06401 1/20 0.44
PTGS1 P23219 1/20 0.44
HSD17B10 Q99714 1/20 0.44
IDO1 P14902 1/20 0.43
PFKFB3 Q16875 1/20 0.43
PFKFB4 Q16877 1/20 0.43
MAPT P10636 3/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22169843 0.86 LDLR (0.51) NOTUMALDH1A1PFKFB3PFKFB4MAPT
SCHEMBL22972012 0.80 SMN1; SMN2 (0.49) NOTUML3MBTL1TDP1KIF11ALDH1A1
SCHEMBL21363204 0.79 NOTUM (0.57) NOTUML3MBTL1TDP1ALDH1A1GAA
SCHEMBL21348370 0.77 ALOX5 (0.63) L3MBTL1ALDH1A1GAAMAPK1PGR
SCHEMBL4513826 0.76 L3MBTL1 (0.51) NOTUML3MBTL1TDP1ALDH1A1GAA
SCHEMBL13133320 0.75 CYP1A2 (0.50) L3MBTL1TDP1KIF11ALDH1A1HSD17B10
SCHEMBL7936413 0.75 KIF11 (0.55) KIF11ALDH1A1MAPTKDM4EHPGD
SCHEMBL22169844 0.74 LDLR (0.50) SIRT2SIRT1SIRT3
SCHEMBL1757167 0.74 MAPT (0.64) NOTUMTDP1ALDH1A1GAAHSD17B10
SCHEMBL31721306 0.74 MAPT (0.64) NOTUMTDP1ALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002271-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2022-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002271-A1 HETEROCYCLIC INHIBITORS OF PCSK9 PCSK9, PCSK6, PCSK7 NOTUM 310/4885ESRRA 3334/4885L3MBTL1 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.